The design, synthesis and testing of deoxy-CBD

further evidence for a region of steric interference at the cannabinoid receptor

P H Reggio, R D Bramblett, H Yuknavich, H H Seltzman, D N Fleming, S R Fernando, Lesley Ann Stevenson, Roger Guy Pertwee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cannabidiol CBD, a non-psychoactive constituent of marihuana, has been reported to possess essentially no affinity for cannabinoid CB1 receptor binding sites in the brain. Our hypothesis concerning CBD's lack of affinity for the cannabinoid CB1 receptor is that CBD is not capable of clearing a region of steric interference at the CB1 receptor and thereby not able to bind to this receptor. We have previously characterized this region of steric interference at the CB1 receptor [P.H. Reggio, A.M. Panu, S. Miles J. Med. Chem. 36, 1761-1771 (1993)] in three dimensions using the Active Analog Approach. We report here a conformational analysis of CBD which, in turn, led to the design of a new analog, desoxy-CBD. Modeling results for desoxy-CBD predict that this compound is capable of clearing the region of steric interference by expending 3.64 kcal/mol of energy in contrast to the 12.39 kcal/mol expenditure required by CBD. Desoxy-CBD was synthesized by condensation of 3-pentylphenol with p-mentha-2,8-dien-1-ol mediated by DMF-dineopental acetal. Desoxy-CBD was found to behave as a partial agonist in the mouse vas deferens assay, an assay which is reported to detect the presence of cannabinoid receptors. The compound produced a concentration related inhibition of electrically-evoked contractions of the mouse vas deferens, possessing an IC50 of 30.9 nM in this assay. Taken together, these results support the hypothesis of the existence of a region of steric interference at the CB1 receptor. While the energy expenditure to clear this region was too high for the parent compound, CBD, the removal of the C6' hydroxyl of CBD produced a molecule (desoxy-CBD) able to clear this region and produce activity, albeit at a reduced level.

Original languageEnglish
Pages (from-to)2025-2032
Number of pages8
JournalLife Sciences
Volume56
Issue number23-24
DOIs
Publication statusPublished - 5 May 1995

Keywords

  • CANNABIDIOL
  • DEOXY-CANNABIDIOL
  • VAS DEFERENS
  • cannabidiol
  • deoxy-cannabidiol
  • vas-deferens

Cite this

The design, synthesis and testing of deoxy-CBD : further evidence for a region of steric interference at the cannabinoid receptor. / Reggio, P H ; Bramblett, R D ; Yuknavich, H ; Seltzman, H H ; Fleming, D N; Fernando, S R ; Stevenson, Lesley Ann; Pertwee, Roger Guy.

In: Life Sciences, Vol. 56, No. 23-24, 05.05.1995, p. 2025-2032.

Research output: Contribution to journalArticle

Reggio, PH, Bramblett, RD, Yuknavich, H, Seltzman, HH, Fleming, DN, Fernando, SR, Stevenson, LA & Pertwee, RG 1995, 'The design, synthesis and testing of deoxy-CBD : further evidence for a region of steric interference at the cannabinoid receptor', Life Sciences, vol. 56, no. 23-24, pp. 2025-2032. https://doi.org/10.1016/0024-3205(95)00185-9
Reggio, P H ; Bramblett, R D ; Yuknavich, H ; Seltzman, H H ; Fleming, D N ; Fernando, S R ; Stevenson, Lesley Ann ; Pertwee, Roger Guy. / The design, synthesis and testing of deoxy-CBD : further evidence for a region of steric interference at the cannabinoid receptor. In: Life Sciences. 1995 ; Vol. 56, No. 23-24. pp. 2025-2032.
@article{b32a70a399374153aae5aff28347fbb1,
title = "The design, synthesis and testing of deoxy-CBD : further evidence for a region of steric interference at the cannabinoid receptor",
abstract = "Cannabidiol CBD, a non-psychoactive constituent of marihuana, has been reported to possess essentially no affinity for cannabinoid CB1 receptor binding sites in the brain. Our hypothesis concerning CBD's lack of affinity for the cannabinoid CB1 receptor is that CBD is not capable of clearing a region of steric interference at the CB1 receptor and thereby not able to bind to this receptor. We have previously characterized this region of steric interference at the CB1 receptor [P.H. Reggio, A.M. Panu, S. Miles J. Med. Chem. 36, 1761-1771 (1993)] in three dimensions using the Active Analog Approach. We report here a conformational analysis of CBD which, in turn, led to the design of a new analog, desoxy-CBD. Modeling results for desoxy-CBD predict that this compound is capable of clearing the region of steric interference by expending 3.64 kcal/mol of energy in contrast to the 12.39 kcal/mol expenditure required by CBD. Desoxy-CBD was synthesized by condensation of 3-pentylphenol with p-mentha-2,8-dien-1-ol mediated by DMF-dineopental acetal. Desoxy-CBD was found to behave as a partial agonist in the mouse vas deferens assay, an assay which is reported to detect the presence of cannabinoid receptors. The compound produced a concentration related inhibition of electrically-evoked contractions of the mouse vas deferens, possessing an IC50 of 30.9 nM in this assay. Taken together, these results support the hypothesis of the existence of a region of steric interference at the CB1 receptor. While the energy expenditure to clear this region was too high for the parent compound, CBD, the removal of the C6' hydroxyl of CBD produced a molecule (desoxy-CBD) able to clear this region and produce activity, albeit at a reduced level.",
keywords = "CANNABIDIOL, DEOXY-CANNABIDIOL, VAS DEFERENS, cannabidiol, deoxy-cannabidiol, vas-deferens",
author = "Reggio, {P H} and Bramblett, {R D} and H Yuknavich and Seltzman, {H H} and Fleming, {D N} and Fernando, {S R} and Stevenson, {Lesley Ann} and Pertwee, {Roger Guy}",
year = "1995",
month = "5",
day = "5",
doi = "10.1016/0024-3205(95)00185-9",
language = "English",
volume = "56",
pages = "2025--2032",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "23-24",

}

TY - JOUR

T1 - The design, synthesis and testing of deoxy-CBD

T2 - further evidence for a region of steric interference at the cannabinoid receptor

AU - Reggio, P H

AU - Bramblett, R D

AU - Yuknavich, H

AU - Seltzman, H H

AU - Fleming, D N

AU - Fernando, S R

AU - Stevenson, Lesley Ann

AU - Pertwee, Roger Guy

PY - 1995/5/5

Y1 - 1995/5/5

N2 - Cannabidiol CBD, a non-psychoactive constituent of marihuana, has been reported to possess essentially no affinity for cannabinoid CB1 receptor binding sites in the brain. Our hypothesis concerning CBD's lack of affinity for the cannabinoid CB1 receptor is that CBD is not capable of clearing a region of steric interference at the CB1 receptor and thereby not able to bind to this receptor. We have previously characterized this region of steric interference at the CB1 receptor [P.H. Reggio, A.M. Panu, S. Miles J. Med. Chem. 36, 1761-1771 (1993)] in three dimensions using the Active Analog Approach. We report here a conformational analysis of CBD which, in turn, led to the design of a new analog, desoxy-CBD. Modeling results for desoxy-CBD predict that this compound is capable of clearing the region of steric interference by expending 3.64 kcal/mol of energy in contrast to the 12.39 kcal/mol expenditure required by CBD. Desoxy-CBD was synthesized by condensation of 3-pentylphenol with p-mentha-2,8-dien-1-ol mediated by DMF-dineopental acetal. Desoxy-CBD was found to behave as a partial agonist in the mouse vas deferens assay, an assay which is reported to detect the presence of cannabinoid receptors. The compound produced a concentration related inhibition of electrically-evoked contractions of the mouse vas deferens, possessing an IC50 of 30.9 nM in this assay. Taken together, these results support the hypothesis of the existence of a region of steric interference at the CB1 receptor. While the energy expenditure to clear this region was too high for the parent compound, CBD, the removal of the C6' hydroxyl of CBD produced a molecule (desoxy-CBD) able to clear this region and produce activity, albeit at a reduced level.

AB - Cannabidiol CBD, a non-psychoactive constituent of marihuana, has been reported to possess essentially no affinity for cannabinoid CB1 receptor binding sites in the brain. Our hypothesis concerning CBD's lack of affinity for the cannabinoid CB1 receptor is that CBD is not capable of clearing a region of steric interference at the CB1 receptor and thereby not able to bind to this receptor. We have previously characterized this region of steric interference at the CB1 receptor [P.H. Reggio, A.M. Panu, S. Miles J. Med. Chem. 36, 1761-1771 (1993)] in three dimensions using the Active Analog Approach. We report here a conformational analysis of CBD which, in turn, led to the design of a new analog, desoxy-CBD. Modeling results for desoxy-CBD predict that this compound is capable of clearing the region of steric interference by expending 3.64 kcal/mol of energy in contrast to the 12.39 kcal/mol expenditure required by CBD. Desoxy-CBD was synthesized by condensation of 3-pentylphenol with p-mentha-2,8-dien-1-ol mediated by DMF-dineopental acetal. Desoxy-CBD was found to behave as a partial agonist in the mouse vas deferens assay, an assay which is reported to detect the presence of cannabinoid receptors. The compound produced a concentration related inhibition of electrically-evoked contractions of the mouse vas deferens, possessing an IC50 of 30.9 nM in this assay. Taken together, these results support the hypothesis of the existence of a region of steric interference at the CB1 receptor. While the energy expenditure to clear this region was too high for the parent compound, CBD, the removal of the C6' hydroxyl of CBD produced a molecule (desoxy-CBD) able to clear this region and produce activity, albeit at a reduced level.

KW - CANNABIDIOL

KW - DEOXY-CANNABIDIOL

KW - VAS DEFERENS

KW - cannabidiol

KW - deoxy-cannabidiol

KW - vas-deferens

U2 - 10.1016/0024-3205(95)00185-9

DO - 10.1016/0024-3205(95)00185-9

M3 - Article

VL - 56

SP - 2025

EP - 2032

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 23-24

ER -